{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:46:25Z","timestamp":1790023585267,"version":"4.0.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>We evaluated the expression of programmed cell death protein-1 (PD-1), programmed cell death ligand 1 (PD-L1), and NY-ESO-1 antigen; the infiltration of CD3+ T cells; and the microsatellite instability (MSI) phenotype, as well as the relationship of each factor to survival in malignant melanoma patients. Malignant melanoma samples from 89 patients were stained by immunohistochemistry to evaluate PD-1, PD-L1, CD3+ tumor-infiltrating lymphocytes (TILs), NY-ESO-1, and MSI. PD-1 and PD-L1 were expressed in 19.1 and 32.6% of the 89 samples, respectively. There was a significant correlation between PD-1 and PD-L1 expression (<jats:italic toggle=\"yes\">r<\/jats:italic>\u2009=\u20090.207, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.046). High infiltration of CD3+ T cells was observed in 41.6% of the samples, and increased cell infiltration was associated with increased PD-1 expression (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.001). NY-ESO-1 antigen was detected in 13.5% of all samples, and the expression of NY-ESO-1 was positively correlated with the expression of PD-1 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001). In our research, MSI was detected in 18 samples (20.2%). Survival analysis showed that a high infiltration of CD3+ T cells was related to longer progression-free survival (PFS) [24.0\u2009months, 95% confidence interval (CI): 7.4\u201340.6 vs. 11.0 months, 95% CI: 7.1\u201312.9, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.031], similarly, the median overall survival (OS) of the CD3+ T cell high-infiltration patients was also longer (53.0 vs. 38.0 months), but with no statistical significance (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.200). The results for the immune markers mentioned above provide a theoretical basis for the prognosis and immunotherapy selection of malignant melanoma patients.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000620","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:47:09Z","timestamp":1558003629000},"page":"85-101","source":"Crossref","is-referenced-by-count":10,"title":["The programmed cell death protein-1\/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases"],"prefix":"10.1097","volume":"30","author":[{"given":"Yu","family":"Ren","sequence":"first","affiliation":[{"name":"Department of the Comprehensive Cancer Center, Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lv","sequence":"additional","affiliation":[{"name":"Yi Xing Tumor Hospital, Yixing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuheng","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of the Comprehensive Cancer Center, Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School"},{"name":"The Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of the Comprehensive Cancer Center, Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyun","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of the Comprehensive Cancer Center, Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma.","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014.","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R3-20230902","first-page":"385","article-title":"Clinical practice guidelines in oncology: melanoma.","volume":"15","year":"2010","journal-title":"Chinese Clin Oncol"},{"key":"R4-20230902","first-page":"385","article-title":"C-KIT gene amplification in 262 Chinese melanoma patients.","volume":"15","author":"Li","year":"2010","journal-title":"Chinese Clin Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1158\/1078-0432.CCR-16-0663","article-title":"FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma.","volume":"23","author":"Chuk","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R13-20230902","first-page":"177","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"105","author":"Robert","year":"2015","journal-title":"Br J Cancer"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.21283","article-title":"The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.","volume":"104","author":"Piras","year":"2005","journal-title":"Cancer"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/sj.bjc.6604738","article-title":"Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer.","volume":"99","author":"Lee","year":"2008","journal-title":"Br J Cancer"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ijc.29118","article-title":"NY-ESO-l specific anti-body and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1fowlpox virus.","volume":"136","author":"Chen","year":"2015","journal-title":"Int J Cancer"},{"key":"R21-20230902","first-page":"104","article-title":"Current advances in basic and clinical study of NY-ESO-1.","volume":"22","author":"Yu","year":"2015","journal-title":"Chin J Cancer Biother"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","article-title":"A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.","volume":"187","author":"Stockert","year":"1998","journal-title":"J Exp Med"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mehy.2016.05.023","article-title":"Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma.","volume":"93","author":"Kubecek","year":"2016","journal-title":"Med Hypotheses"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3892\/ol.2014.2286","article-title":"Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma.","volume":"8","author":"Peng","year":"2014","journal-title":"Oncol Lett"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/bjc.2013.51","article-title":"NY-ESO-1 antibody as a novel tumour marker of gastric cancer.","volume":"108","author":"Fujiwara","year":"2013","journal-title":"Br J Cancer"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/his.12365","article-title":"The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma.","volume":"65","author":"Kao","year":"2014","journal-title":"Histopathology"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4161\/onci.21059","article-title":"NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.","volume":"1","author":"Lai","year":"2012","journal-title":"Oncoimmunology"},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/CMR.0000000000000379","article-title":"Current status and future direction in the management of malignant melanoma.","volume":"27","author":"Gladfelter","year":"2017","journal-title":"Melanoma Res"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jamaoncol.2015.0565","article-title":"Therapeutic advances and treatment options in metastatic melanoma.","volume":"1","author":"Johnson","year":"2015","journal-title":"JAMA Oncol"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00262-017-2085-9","article-title":"A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and \u03b1-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.","volume":"67","author":"Gasser","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma.","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"R32-20230902","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1093\/annonc\/mdu452","article-title":"PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.","volume":"25","author":"Massi","year":"2014","journal-title":"Ann Oncol"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jaad.2014.01.861","article-title":"Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival.","volume":"70","author":"Micheletti","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R34-20230902","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles.","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/modpathol.2015.110","article-title":"Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.","volume":"28","author":"Hojabr","year":"2015","journal-title":"Mod Pathol"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/CMR.0000000000000197","article-title":"Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.","volume":"25","author":"Thieraufa","year":"2015","journal-title":"Melanoma Res"},{"key":"R38-20230902","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites.","volume":"21","author":"Kluger","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R40-20230902","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma.","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"key":"R41-20230902","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00262-011-1007-5","article-title":"Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.","volume":"60","author":"Malaspina","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"R42-20230902","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy.","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R43-20230902","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer.","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"R44-20230902","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol"},{"key":"R45-20230902","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-62703-727-3_16","article-title":"Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.","volume":"1102","author":"Schatton","year":"2014","journal-title":"Methods Mol Biol"},{"key":"R46-20230902","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.12641","article-title":"High expression of FOXP3 in primary melanoma is associated with tumour progression.","volume":"170","author":"Gerber","year":"2014","journal-title":"Br J Dermatol"},{"key":"R47-20230902","first-page":"1026","article-title":"The expression of Tregs and CD8+T cells in malignant melanoma and its relationship with prognosis.","volume":"43","author":"Su","year":"2015","journal-title":"Tianjin Med J"},{"key":"R48-20230902","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4049\/jimmunol.1402664","article-title":"The tumor antigen NY-ESO-1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer.","volume":"196","author":"Fonteneau","year":"2016","journal-title":"J Immunol"},{"key":"R49-20230902","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1158\/1078-0432.CCR-13-2508","article-title":"Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.","volume":"20","author":"Weide","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R50-20230902","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1590\/abd1806-4841.20176183","article-title":"Melanoma: tumor microenvironment and new treatments.","volume":"92","author":"Giavina-Bianchi","year":"2017","journal-title":"An Bras Dermatol"},{"key":"R51-20230902","first-page":"11","article-title":"Expression of the cancer\/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)\u2013correlation with prognostic factors.","volume":"7","author":"Velazquez","year":"2007","journal-title":"Cancer Immun"},{"key":"R52-20230902","doi-asserted-by":"crossref","first-page":"761378","DOI":"10.1155\/2015\/761378","article-title":"Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.","volume":"2015","author":"Giavina-Bianchi","year":"2015","journal-title":"J Immunol Res"},{"key":"R53-20230902","first-page":"376","article-title":"Research progress of MSI colorectal cancer.","volume":"31","author":"Ma","year":"2017","journal-title":"J Pract Oncol"},{"key":"R54-20230902","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U","article-title":"Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma.","volume":"91","author":"Smyrk","year":"2001","journal-title":"Cancer"},{"key":"R55-20230902","doi-asserted-by":"crossref","first-page":"e29256","DOI":"10.4161\/onci.29256","article-title":"Characterization of an adaptive immune response in microsatellite-instable colorectal cancer.","volume":"3","author":"Boissi\u00e8re-Michot","year":"2014","journal-title":"Oncoimmunology"},{"key":"R56-20230902","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2007.123794","article-title":"High prevalence of foxp3 and IL17 in MMR-proficient colorectal carcinomas.","volume":"57","author":"Le Gouvello","year":"2008","journal-title":"Gut"},{"key":"R57-20230902","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"R58-20230902","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R59-20230902","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"R60-20230902","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CMR.0000000000000298","article-title":"Microsatellite instability in melanoma: a comprehensive review.","volume":"26","author":"Kubec\u010dek","year":"2016","journal-title":"Melanoma Res"},{"key":"R61-20230902","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2559.2007.02683.x","article-title":"DNA mismatch repair protein expression and microsatellite instability in primary mucosal melanomas of the head and neck.","volume":"50","author":"Marani","year":"2007","journal-title":"Histopathology"},{"key":"R62-20230902","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/00015550152572840","article-title":"Microsatellite instability in malignant melanomas.","volume":"81","author":"Kroiss","year":"2001","journal-title":"Acta Derm Venereol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:01:20Z","timestamp":1693627280000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000620","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}